Mobidiag Implements High Throughput Manufacturing Lines to Answer Growing Needs for Novodiag® Cartridges
Mobidiag Ltd, a Finnish molecular diagnostics for infectious diseases company, today announced it has signed an agreement with Ginolis, expert in assembly automation and high precision liquid handling solutions. Through the implementation of cutting-edge production lines from Ginolis, Mobidiag will be able to answer growing needs in molecular diagnostics for routine use and anticipate the production of upcoming Novodiag® test cartridges.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180304005019/en/
Novodiag® disposable cartridge for diagnostics of infectious diseases (Photo: Mobidiag)
Launched in December 2017, the new Novodiag® solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour, compared to days with well-established culture methods. Novodiag® helps make treatment decisions faster and more accurate, avoiding for example the unnecessary use of antibiotics.
“The innovative Novodiag cartridge has been developed at Mobidiag thanks to the combination of multidisciplinary teams and expertise. The cartridge includes state-of-the-art technologies such as qPCR and microarray, bringing with them some specific requirements and constraints. We then needed to successfully automate our processes and move from a small scale production capacity to industrial volumes without compromising quality and costs. Thanks to its cutting-edge modular platforms and expertise in diagnostics processes, we are confident that Ginolis will bring the most relevant solution to support us in our growing activity”, says Tuomas Tenkanen, CEO at Mobidiag.
The manufacturing solution developed for Mobidiag is based on Ginolis’ modular Xanthia automation platform. Its compact and modular design allows for high quality automation within a small footprint, saving valuable space in the clean room environment. In addition to Ginolis’ patented dispensing technology, the line is equipped with laser welding, precision assembly, ultrasonic welding and line confocal imaging (LCI) for quality inspection.
“The demand for molecular diagnostics is on the rise and we are proud to continue our long-standing cooperation with Mobidiag. Both companies share a dedication to innovation and high quality”, says Ginolis CEO Teijo Fabritius. “This line is a testament to the scalability of our flexible modular solutions and ability to integrate the entire manufacturing process on one platform.”
Antibiotic resistance is one of the greatest threats to the world's health. According to the World Health Organization, the number of antibiotic-resistant bacteria grows at an alarming rate worldwide and all efforts should be taken to stop this development. Fast and reliable diagnostics are needed to detect resistance and thereby reduce the use of antibiotics.
With rapid tests and high-capacity production lines, Mobidiag is able to respond to rapidly growing requirements for infection diagnosis, including antibiotic resistance. A Novodiag® cartridge currently under development and planned to be released in mid-2018.
The Novodiag® solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour.
Combining qPCR and microarray technologies, Novodiag offers an all in one solution for on-demand targeted and syndromic testing.
This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is particularly suitable for low volumes and on demand testing for clinical laboratories.
Learn more about Novodiag ® .
About Mobidiag Ltd.
Established in 2000, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D center in France and subsidiaries in UK and Sweden.
Combining Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line of products for fast, reliable and cost-efficient diagnostics for infectious diseases and antibiotic resistances. Mobidiag is able to cover all laboratories requirements no matter their size, throughput and centralized/ decentralized organization.
To learn more, visit www.mobidiag.com
About Ginolis Ltd.
Ginolis specializes in providing high-quality automation, liquid handling and quality control solutions for the production and processing of healthcare consumables. The company is privately owned and headquartered in Oulu, Finland, with sites in Uppsala, Sweden, San Diego, USA and Suzhou, China.
To learn more, visit Ginolis.com
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on